Rep. April McClain Delaney Buys Bio-Techne Corp (NASDAQ:TECH) Shares

Posted by Linda Flegge on Nov 6th, 2025

Representative April McClain Delaney (D-Maryland) recently bought shares of Bio-Techne Corp (NASDAQ:TECH). In a filing disclosed on November 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on October 22nd.

Representative April McClain Delaney also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Teledyne Technologies (NYSE:TDY) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/31/2025.
Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/31/2025.
Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/31/2025.
Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 10/31/2025.
Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 10/29/2025.
Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/29/2025.
Purchased $1,001 – $15,000 in shares of Labcorp (NYSE:LH) on 10/29/2025.
Sold $1,001 – $15,000 in shares of Middleby (NASDAQ:MIDD) on 10/22/2025.
Purchased $15,001 – $50,000 in shares of Nasdaq (NASDAQ:NDAQ) on 10/22/2025.

Bio-Techne Stock Down 1.9%

Shares of Bio-Techne stock opened at $59.94 on Thursday. Bio-Techne Corp has a twelve month low of $46.01 and a twelve month high of $80.80. The company has a quick ratio of 2.38, a current ratio of 3.46 and a debt-to-equity ratio of 0.18. The company’s 50 day moving average is $57.50 and its 200 day moving average is $53.66. The company has a market cap of $9.33 billion, a price-to-earnings ratio of 130.31, a price-to-earnings-growth ratio of 3.63 and a beta of 1.51.

Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $0.42 EPS for the quarter, hitting analysts’ consensus estimates of $0.42. The business had revenue of $286.56 million during the quarter, compared to the consensus estimate of $292.02 million. Bio-Techne had a net margin of 6.02% and a return on equity of 13.43%. The firm’s revenue was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.42 EPS. Research analysts anticipate that Bio-Techne Corp will post 1.67 EPS for the current year.

Bio-Techne Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 28th. Stockholders of record on Monday, November 17th will be issued a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, November 17th. Bio-Techne’s payout ratio is presently 69.57%.

Analyst Ratings Changes

A number of research firms recently commented on TECH. Citigroup upgraded Bio-Techne from a “neutral” rating to a “buy” rating and upped their price objective for the company from $55.00 to $70.00 in a research report on Thursday, August 21st. Evercore ISI upped their price target on shares of Bio-Techne from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Zacks Research upgraded shares of Bio-Techne from a “strong sell” rating to a “hold” rating in a research note on Monday, October 6th. TD Cowen boosted their target price on shares of Bio-Techne from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, October 14th. Finally, Royal Bank Of Canada raised shares of Bio-Techne from a “hold” rating to a “moderate buy” rating in a report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bio-Techne currently has an average rating of “Moderate Buy” and a consensus target price of $70.58.

View Our Latest Stock Report on Bio-Techne

Institutional Investors Weigh In On Bio-Techne

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its stake in shares of Bio-Techne by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 11,375,279 shares of the biotechnology company’s stock worth $666,933,000 after acquiring an additional 721,012 shares during the period. Select Equity Group L.P. lifted its holdings in shares of Bio-Techne by 129.8% in the first quarter. Select Equity Group L.P. now owns 5,366,003 shares of the biotechnology company’s stock worth $314,609,000 after buying an additional 3,030,644 shares in the last quarter. Invesco Ltd. boosted its position in shares of Bio-Techne by 9.7% during the first quarter. Invesco Ltd. now owns 4,190,115 shares of the biotechnology company’s stock worth $245,666,000 after acquiring an additional 369,651 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in Bio-Techne by 18.5% during the first quarter. Massachusetts Financial Services Co. MA now owns 3,025,409 shares of the biotechnology company’s stock valued at $177,380,000 after acquiring an additional 472,847 shares in the last quarter. Finally, Champlain Investment Partners LLC increased its holdings in Bio-Techne by 8.9% in the 2nd quarter. Champlain Investment Partners LLC now owns 2,665,684 shares of the biotechnology company’s stock valued at $137,149,000 after acquiring an additional 217,362 shares during the last quarter. 98.95% of the stock is owned by institutional investors.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About Bio-Techne

(Get Free Report)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.